TY - JOUR
T1 - Wnt/Β-Catenin activation promotes prostate tumor progression in a mouse model
AU - Yu, X.
AU - Wang, Y.
AU - Degraff, D. J.
AU - Wills, M. L.
AU - Matusik, R. J.
N1 - Funding Information:
We thank Dr Angela Barth, the Stanford University, for kindly providing the mutant b-catenin expressing vector, Tom Case and Manik Paul for technical support, Dr Barbara Fingleton and Dr Lynn Matrisian for advice and discussion. Grant support was provided by NIH to RJM (Grant Numbers: 2R01 CA76142-11; 2R01-DK055748-10), DOD to RJM (Grant Number: PC074022), and the Joe C. Davis Foundation. David DeGraff, PhD was supported by the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship.
PY - 2011/4/21
Y1 - 2011/4/21
N2 - Our previous studies have found that activation of Wnt/Β-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen (LPB-Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/Β-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear Β-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/Β-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/Β-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) Β-catenin prostates, MMP7, a Wnt/Β-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA Β-catenin mice. Although Β-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA Β-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA Β-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/Β-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma.
AB - Our previous studies have found that activation of Wnt/Β-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen (LPB-Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/Β-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear Β-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/Β-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/Β-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) Β-catenin prostates, MMP7, a Wnt/Β-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA Β-catenin mice. Although Β-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA Β-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA Β-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/Β-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma.
UR - https://www.scopus.com/pages/publications/79955479314
UR - https://www.scopus.com/pages/publications/79955479314#tab=citedBy
U2 - 10.1038/onc.2010.560
DO - 10.1038/onc.2010.560
M3 - Article
C2 - 21151173
AN - SCOPUS:79955479314
SN - 0950-9232
VL - 30
SP - 1868
EP - 1879
JO - Oncogene
JF - Oncogene
IS - 16
ER -